SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-21-000097
Filing Date
2021-04-12
Accepted
2021-04-12 16:05:12
Documents
14
Period of Report
2021-04-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20210406.htm   iXBRL 8-K 36070
  Complete submission text file 0001479290-21-000097.txt   179101

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20210406.xsd EX-101.SCH 2458
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20210406_cal.xml EX-101.CAL 744
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20210406_def.xml EX-101.DEF 1689
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20210406_lab.xml EX-101.LAB 24275
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20210406_pre.xml EX-101.PRE 12680
7 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20210406_htm.xml XML 11325
Mailing Address 7555 GATEWAY BLVD NEWARK CA 94560
Business Address 1222 DEMONBREUN STREET SUITE 1001 NASHVILLE TN 37203 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 21820766
SIC: 2834 Pharmaceutical Preparations